Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Alphatec Opts For Scient’X Spine Stabilization Device After Acquisition Fails

This article was originally published in The Gray Sheet

Executive Summary

Spinal fusion device maker Alphatec Holding gains the rights to manufacture and distribute Scient'X's flagship dynamic stabilization product portfolio in the United States under one of three licensing agreements signed in lieu of a planned acquisition

You may also be interested in...



Spine Deal Redux: Alphatec Makes Another Go At Acquiring Scient'x

Alphatec Spine aims to significantly expand its international sales presence and create the third-largest independent spinal device firm through its $116 million acquisition of French spinal implant company Scient'x

Spine Deal Redux: Alphatec Makes Another Go At Acquiring Scient'x

Alphatec Spine aims to significantly expand its international sales presence and create the third-largest independent spinal device firm through its $116 million acquisition of French spinal implant company Scient'x

Ideal Medical Products accepts buyout deal

Private equity fund HealthpointCapital acquires Paris-based Ideal Medical Products, the principal shareholder of spinal implant developer Scient'X. The two-step deal calls for the payment of $62 million to acquire the privately held Ideal Medical shares controlled by the Carli family, followed by initiation of a tender offer for the publicly held, minority interest in the company at $31.81 per share. Spinal fusion device maker Alphatec had sought to buy Scient'X in 2006 for $180 million, but the deal was later scuttled in favor of a licensing deal for Scient'X flagship dynamic stabilization product portfolio. HealthpointCapital, which also is Alphatec's principal stockholder, notes that this deal "will allow our firm to directly invest in and grow Scient'X" (1"The Gray Sheet" Jan. 29, 2007, p. 15)

Latest Headlines
See All
UsernamePublicRestriction

Register

MT024424

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel